<DOC>
	<DOCNO>NCT00066326</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy 17-N-allylamino-17-demethoxygeldanamycin use different way stop cancer cell divide stop grow die . Combining imatinib mesylate chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin give together imatinib mesylate treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate 17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) administer imatinib mesylate patient chronic myelogenous leukemia . - Determine pharmacokinetics regimen patient . OUTLINE : This open-label , nonrandomized , multicenter , dose-escalation study 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) . Patients receive oral imatinib mesylate day 1-21 17-AAG IV 1 hour day 1 , 4 , 8 , 12 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional cohort 6-10 patient receive treatment recommend phase II dose . PROJECTED ACCRUAL : Approximately 21-42 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia , include follow phase : Blastic phase Greater 30 % blast peripheral blood bone marrow Previously untreated disease OR refractory relapse recent therapy Accelerated phase , define 1 following : At least 15 , less 30 % , blast peripheral blood bone marrow At least 30 % blast promyelocytes peripheral blood bone marrow Greater 20 % peripheral blood basophilia Chronic phase No major cytogenetic response ( le 65 % Philadelphia chromosome negative ) 12 month prior imatinib mesylate therapy Philadelphia chromosome positive routine cytogenetics PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Not specify Hepatic Bilirubin great 1.5 mg/dL ALT AST great 2.5 time upper limit normal Renal Creatinine le 1.5 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known allergy egg Able swallow pill No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled medical illness PRIOR CONCURRENT THERAPY : Biologic therapy No prior stem cell transplantation Chemotherapy More 4 week since prior chemotherapy ( except hydroxyurea anagrelide ) ( least 6 week nitrosoureas mitomycin ) Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy Surgery No prior liver , kidney , lung transplantation More 14 day since prior major surgery ( e.g. , thoracotomy intraabdominal surgery ) Other Prior imatinib mesylate administer within past 4 week allow No concurrent tacrolimus cyclosporine immunosuppressive agent No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent agent alter CYP3A4 activity , include follow : Grapefruit juice Ketoconazole Fluconazole Itraconazole Erythromycin Clarithromycin Cimetidine Terfenadine Astemizole HIV protease inhibitor ( e.g. , indinavir nelfinavir )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>